Ionis Pharmaceuticals, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Ionis Pharmaceuticals, Inc.
- Company name
- Ionis Pharmaceuticals, Inc.
- Organisation type
- Industry
- Registered legal name
- Ionis Pharmaceuticals, Inc.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Website
- http://www.ionispharma.com/
- SEC filer number (CIK)
- 0000874015
- Legal Entity Identifier (LEI)
- 549300SI4ZGLG0BLUZ92
- Wikidata ID
- Q22079531
Related records
Trials (158)
- A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
- A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
- A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
- A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
- A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
- A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients
- A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants
- A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
- A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
- A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
- A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
- A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
- A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
- A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
- A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
- A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis